The company’s AlphaFold platform impressed two years ago, and is now extending its machine learning tech into small-molecule drug discovery with big pharma partners.

Offering a challenging but blossoming free market model, strong academic institutions and an excellent track record in patents, the Swiss Biotech industry is one to watch. 

Sanofi India's managing director is moving on after an eventful innings that saw the company re-orient operations, moving out of certain non-strategic areas to focus on core therapies. Pre-pandemic early digital adoption appears to have played out well too for the French group’s listed Indian arm.

More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.